(Q44170281)

30 November 2017

title

Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors (English)

1 reference

30 November 2017

1 reference

2

Raymond F Schinazi

1 reference

30 November 2017

Selwyn J Hurwitz

1

1 reference

30 November 2017

language of work or name

1 reference

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

56

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

115-127

1 reference

Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

HIV resistance to zidovudine: the role of pyrophosphorolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The challenge of viral reservoirs in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Clinical trial simulation in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Virus dynamics and drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

How does HIV cause AIDS? The homing theory

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Benchmarks for antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Prevalence and predictive value of intermittent viremia with combination hiv therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Cellular pharmacology of the D- and L-enantiomers of beta-5-o-carboranyl-2'-deoxyuridine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The bottleneck in AZT activation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

A model of HIV-1 pathogenesis that includes an intracellular delay.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

Modeling plasma virus concentration during primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900103-1

7 January 2021

10.1016/S0166-3542(02)00103-1

Identifiers

DOI

1 reference

release_jzuqxk4h3va4ncsauk6txxy3mm

30 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jzuqxk4h3va4ncsauk6txxy3mm

24 November 2022

mapped directly with Wikidata item

1 reference